Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating

Stock Track05-01

Pacira Pharmaceuticals' stock soared 5.41% during intraday trading on Friday, driven by a positive market reaction to the company's latest financial results and analyst sentiment.

The surge follows the company's release of first-quarter earnings that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the consensus estimate of $0.55. Furthermore, revenue for the quarter rose to $177.4 million, surpassing the forecast of $171.8 million and showing growth from $168.9 million a year earlier.

Adding to the positive momentum, the company maintained its full-year 2026 revenue guidance of $745 million to $770 million. Analyst firm Needham also maintained its Buy rating on the stock, reinforcing confidence in the company's financial outlook among investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121020406?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121020406","market":"sg","top_or_hot":-1,"title":"Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating","media":"Stock Track","content":"<p>Pacira Pharmaceuticals' stock soared 5.41% during intraday trading on Friday, driven by a positive market reaction to the company's latest financial results and analyst sentiment.</p><p>The surge follows the company's release of first-quarter earnings that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the consensus estimate of $0.55. Furthermore, revenue for the quarter rose to $177.4 million, surpassing the forecast of $171.8 million and showing growth from $168.9 million a year earlier.</p><p>Adding to the positive momentum, the company maintained its full-year 2026 revenue guidance of $745 million to $770 million. Analyst firm Needham also maintained its Buy rating on the stock, reinforcing confidence in the company's financial outlook among investors.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pacira Pharmaceuticals' stock soared 5.41% during intraday trading on Friday, driven by a positive market reaction to the company's latest financial results and analyst sentiment.</p><p>The surge follows the company's release of first-quarter earnings that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the consensus estimate of $0.55. Furthermore, revenue for the quarter rose to $177.4 million, surpassing the forecast of $171.8 million and showing growth from $168.9 million a year earlier.</p><p>Adding to the positive momentum, the company maintained its full-year 2026 revenue guidance of $745 million to $770 million. Analyst firm Needham also maintained its Buy rating on the stock, reinforcing confidence in the company's financial outlook among investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCRX","symbol_name":"Pacira Pharmaceuticals","start_time":0,"source_url":"","article_id":"1121020406","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121020406","pubTimestamp":1777642474,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Pacira Pharmaceuticals' stock soared 5.41% during intraday trading on Friday, driven by a positive market reaction to the company's latest financial results and analyst sentiment.The surge follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCRX":"Pacira Pharmaceuticals"},"translate_title":"个股追踪|Pacira Pharmaceuticals盘中大涨5.41%，Q1盈利超预期、营收增长，维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1},"content_text":"Pacira Pharmaceuticals' stock soared 5.41% during intraday trading on Friday, driven by a positive market reaction to the company's latest financial results and analyst sentiment.The surge follows the company's release of first-quarter earnings that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the consensus estimate of $0.55. Furthermore, revenue for the quarter rose to $177.4 million, surpassing the forecast of $171.8 million and showing growth from $168.9 million a year earlier.Adding to the positive momentum, the company maintained its full-year 2026 revenue guidance of $745 million to $770 million. Analyst firm Needham also maintained its Buy rating on the stock, reinforcing confidence in the company's financial outlook among investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121020406","isCrawlerRequest":true}